Abstract
Type 2-diabetes (T2D) is thought to be a relevant risk factor for multiple myeloma (MM), but the relationship between both traits is still not well understood. Thus, we decided to conduct a population-based case-control study in a population of 1420 MM patients (705 women and 715 men) and 1858 controls (916 women and 942 men) to evaluate whether 58 genome-wide association studies (GWAS)-identified common variants for T2D influence the risk of developing MM. Logistic regression analyses showed that carriers of the KCNQ1rs2237892T allele or CDKN2A-2Brs2383208G/G, IGF-1rs35767T/T and MADDrs7944584T/T genotypes had an increased risk of MM (OR=1.32, 95%CI 1.01-1.71, P=0.039; OR=1.86, 95%CI 1.12-3.11, P=0.016; OR=2.13, 95%CI 1.35-3.37, P=0.001 and OR=1.33, 95%CI 1.06-1.67, P=0.014, respectively) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a decreased risk for the disease (OR=0.85, 95%CI 0.73-0.99, P=0.38; OR=0.84, 95%CI 0.72-0.99, P=0.034; OR=0.81, 95%CI 0.68-0.98, P=0.032; OR=0.78, 95%CI 0.64-0.95, P=0.013; and OR=0.76, 95%CI 0.58-0.99, P=0.042, respectively). The associations of these T2D-related variants with an increased or decreased risk of MM were due to non-diabetogenic alleles, which suggests a non-diabetogenic mechanism underlying the effect of these variants to determine the risk of the disease. A gender-stratified analysis also revealed a significant gender effect modification for ADAM30rs2641348, and NOTCH2rs10923931 SNPs (Pinteraction=0.001 and 0.0004 and Phet=0.19 and 0.60, respectively), which also underlies the importance of considering gender as a factor modifying the risk for MM. Men harbouring the ADAM30rs2641348C and NOTCH2rs10923931T alleles had a decreased risk of MM (OR=0.71, 95%CI 0.54-0.94, P=0.015 and OR=0.66, 95%CI 0.50-0.86, P=0.0019) whereas an opposite but not significant effect was observed in women. Finally, SNP-SNP interaction analysis revealed overall significant two- and three-locus interaction models to increase the risk of MM (FAM148Brs11071657-KCNJ11rs5219, and SLC30A8rs13266634-KCNJ11rs5219-FTOrs8050136; P=0.01 and 0.001, respectively) whereas a significant four-locus model was also found to increase the risk of MM in men (FADS1rs174550-TSPAN8rs7961581-PROX1rs340874-KCNJ11rs5219, P=0.001). Although further studies in independent populations are warranted to replicate these findings, these results suggest that TD2-related variants may influence the risk of developing MM, likely through non-diabetogenic mechanisms.
. | CASES . | CONTROLS . | . | ||
---|---|---|---|---|---|
Region* | Gender M/F (Total) | Mean Age (± STD) | Gender M/F (Total) | Mean Age (± STD) | Control type |
Italy | 117/107 (224) | 62.60±9.90 | 127/105 (232) | 58.75±10.92 | General population |
Poland | 173/198 (371) | 62.35±10.39 | 124/226 (350) | 50.68±19.43 | Blood donors |
Spain | 139/133 (272) | 63.06±11.04 | 218/192 (410) | 63.12±11.94 | Hospitalized subjects |
France | 42/33 (75) | 55.80±9.04 | 95/89 (184) | 44.07±15.22 | Blood donors |
Portugal | 32/35 (67) | 65.79±11.16 | 52/42 (94) | 60.88±07.88 | Blood donors |
Hungary | 49/87 (136) | 65.83±11.19 | 50/51 (101) | 73.18±10.10 | Hospitalized subjects |
Denmark | 163/112 (275) | 55.20±07.32 | 276/211 (487) | 43.26±11.84 | General population |
Total | 715/705 (1420) | 61.06±10.57 | 942/916 (1858) | 53.56±16.45 |
. | CASES . | CONTROLS . | . | ||
---|---|---|---|---|---|
Region* | Gender M/F (Total) | Mean Age (± STD) | Gender M/F (Total) | Mean Age (± STD) | Control type |
Italy | 117/107 (224) | 62.60±9.90 | 127/105 (232) | 58.75±10.92 | General population |
Poland | 173/198 (371) | 62.35±10.39 | 124/226 (350) | 50.68±19.43 | Blood donors |
Spain | 139/133 (272) | 63.06±11.04 | 218/192 (410) | 63.12±11.94 | Hospitalized subjects |
France | 42/33 (75) | 55.80±9.04 | 95/89 (184) | 44.07±15.22 | Blood donors |
Portugal | 32/35 (67) | 65.79±11.16 | 52/42 (94) | 60.88±07.88 | Blood donors |
Hungary | 49/87 (136) | 65.83±11.19 | 50/51 (101) | 73.18±10.10 | Hospitalized subjects |
Denmark | 163/112 (275) | 55.20±07.32 | 276/211 (487) | 43.26±11.84 | General population |
Total | 715/705 (1420) | 61.06±10.57 | 942/916 (1858) | 53.56±16.45 |
Gene name . | dbSNP rs# . | Gene name . | dbSNP rs# . |
---|---|---|---|
ADAM30 | rs2641348 | JAZF1 | rs864745 |
ADAMTS9 | rs4607103 | KCNJ11 | rs5215 |
ADCY5 | rs11708067 | rs5219 | |
ADRA2A | rs10885122 | KCNQ1 | rs2237897 |
ARAPI, CENTD2 | rs1552224 | rs2074196 | |
BCL11A | rs10490072 | rs2237892 | |
CDC123 | rs12779790 | rs2237895 | |
CDKAL1 | rs7754840 | KCNQ1OT1 | rs231362 |
CDKN2A-2B | rs564398 | LTA | rs1041981 |
rs10811661 | MADD | rs7944584 | |
rs2383208 | MCR4 | rs12970134 | |
COL5A1 | rs4240702 | MTNR1B | rs1387153 |
CRY2 | rs11605924 | NOTCH2 | rs10923931 |
DCD | rs1153188 | PKN2 | rs6698181 |
EXT2 | rs1113132 | PPARG | rs1801282 |
FADS1 | rs174550 | PRC1 | rs8042680 |
FAM148B | rs11071657 | PROX1 | rs340874 |
FLJ39370 | rs17044137 | RBMS1 | rs7593730 |
FTO | rs8050136 | SLC2A2 | rs11920090 |
G6PC2 | rs560887 | SLC30A8 | rs13266634 |
GCK | rs1799884 | TCF2 | rs7501939 |
GCKR | rs1260326 | TCF7L2 | rs7903146 |
HHEX | rs1111875 | TCF7L2 | rs12255372 |
HMGA2 | rs1531343 | THADA | rs7578597 |
HNF1A, TCF1 | rs7957197 | TP53INP1 | rs896854 |
IGF1 | rs35767 | TSPAN8 | rs7961581 |
IGF2BP2 | rs4402960 | VEGFA | rs9472138 |
IL13 | rs20541 | WFS1 | rs734312 |
IRS1 | rs2943641 | rs10010131 |
Gene name . | dbSNP rs# . | Gene name . | dbSNP rs# . |
---|---|---|---|
ADAM30 | rs2641348 | JAZF1 | rs864745 |
ADAMTS9 | rs4607103 | KCNJ11 | rs5215 |
ADCY5 | rs11708067 | rs5219 | |
ADRA2A | rs10885122 | KCNQ1 | rs2237897 |
ARAPI, CENTD2 | rs1552224 | rs2074196 | |
BCL11A | rs10490072 | rs2237892 | |
CDC123 | rs12779790 | rs2237895 | |
CDKAL1 | rs7754840 | KCNQ1OT1 | rs231362 |
CDKN2A-2B | rs564398 | LTA | rs1041981 |
rs10811661 | MADD | rs7944584 | |
rs2383208 | MCR4 | rs12970134 | |
COL5A1 | rs4240702 | MTNR1B | rs1387153 |
CRY2 | rs11605924 | NOTCH2 | rs10923931 |
DCD | rs1153188 | PKN2 | rs6698181 |
EXT2 | rs1113132 | PPARG | rs1801282 |
FADS1 | rs174550 | PRC1 | rs8042680 |
FAM148B | rs11071657 | PROX1 | rs340874 |
FLJ39370 | rs17044137 | RBMS1 | rs7593730 |
FTO | rs8050136 | SLC2A2 | rs11920090 |
G6PC2 | rs560887 | SLC30A8 | rs13266634 |
GCK | rs1799884 | TCF2 | rs7501939 |
GCKR | rs1260326 | TCF7L2 | rs7903146 |
HHEX | rs1111875 | TCF7L2 | rs12255372 |
HMGA2 | rs1531343 | THADA | rs7578597 |
HNF1A, TCF1 | rs7957197 | TP53INP1 | rs896854 |
IGF1 | rs35767 | TSPAN8 | rs7961581 |
IGF2BP2 | rs4402960 | VEGFA | rs9472138 |
IL13 | rs20541 | WFS1 | rs734312 |
IRS1 | rs2943641 | rs10010131 |
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.